a ppar activator according to the present invention is appropriate as long as it contains β - cryptoxantine , and also may contain components such as other ppar activators , for example , other than β - cryptoxantine . in the present invention , the ppar to be activated may be either pparα or pparγ , for example , and preferably is both of them . as described above , since β - cryptoxantine has a ppar activating function , the ppar activator according to the present invention has at least one of the functions of inhibiting the secretion of tnf - α and free fatty acid in fat cells , promoting the secretion of adiponectin in fat cells and promoting β oxidation of fat in liver cells , for example . moreover , the ppar activator according to the present invention has a function of inducing at least one of apoptosis , differentiation , shrinkage and the like of a fat cell , for example . in the ppar activator according to the present invention , the β - cryptoxantine to be used is not particularly limited , and examples thereof include those derived from citrus fruits , persimmons , papayas , loquats , red bell peppers and the like . in particular , citrus fruits are preferable . the β - cryptoxantine derived from mandarin - type citrus fruits is more preferable , and that derived from satsuma oranges is particularly preferable . this is because , since an industrial method for manufacturing β - cryptoxantine from citrus fruits has been established as described later ( see , jp 3359298 b , for example ), inexpensive and safe β - cryptoxantine is available . in particular , satsuma oranges contain β - cryptoxantine at a concentration as high as about 1 . 0 to 2 . 9 mg / 100 g . further , as the material , it is possible to use the entire fruit , for example , and it is particularly preferable to use the pulp . incidentally , in the present invention , β - cryptoxantine may be a product obtained by isolation and purification from the above - noted citrus fruits or may be a commercially available product , for example . next , a drug according to the present invention is a drug for preventing or treating at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , for example , and the drug contains the ppar activator according to the present invention . the drug of the present invention may contain not only the ppar activator according to the present invention but also other ppar activators and various additives , for example . in the drug according to the present invention , examples of its specific dosage form can include a tablet , a granule ( including powder ), a capsule , a solution ( including a syrup ) and the like . the drug according to the present invention can be manufactured by using an additive or a base , etc . that is suitable for the respective dosage form as necessary according to a regular method described in the pharmacopoeia of japan or the like . also , a route of administration is not particularly limited but can be , for example , an oral administration or a parenteral administration . examples of the parenteral administration can include intraoral administration , tracheobronchial administration , intrarectal administration , subcutaneous administration , intramuscular administration , intravenous administration and the like . now , a supplement according to the present invention is a supplement for preventing or relieving at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , for example , and the supplement contains the ppar activator according to the present invention . the supplement of the present invention may contain not only the ppar activator according to the present invention but also other ppar activators , various additives , other supplements and the like , for example . examples of the above - noted other supplements can include various vitamins such as vitamin c , amino acids and oligosaccharides . the supplement according to the present invention may be in any form without particular limitation , which can be , for example , tablets , fine grains ( including pulvis ), capsules , solution ( including syrup ) or the like . next , a functional food according to the present invention is a functional food for preventing or relieving at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , and the functional food contains the ppar activator according to the present invention . the functional food of the present invention may contain not only the ppar activator according to the present invention but also other ppar activators , various additives and the like , for example . incidentally , the functional food according to the present invention may be in any form without particular limitation , which can be , for example , noodles , confectionery , functional drinks or the like . now , a food additive according to the present invention is a food additive for preventing or relieving at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , and the food additive contains the ppar activator according to the present invention . the food additive of the present invention may contain not only the ppar activator according to the present invention but also other ppar activators , various additives and the like , for example . the food additive according to the present invention may be in any form without particular limitation , which can be , for example , liquid , paste , powder , flakes , granule or the like . moreover , the food additive according to the present invention includes , for example , food additives for drinks . next , a method for activating a ppar according to the present invention includes , for example , bringing β - cryptoxantine into contact with a fat cell , a liver cell or the like . the method for activating a ppar according to the present invention induces at least one of the functions of inhibiting the secretion of tnf - α and free fatty acid in fat cells , promoting the secretion of adiponectin in fat cells and promoting β oxidation of fat in liver cells , for example . moreover , the method for activating a ppar according to the present invention induces at least one of apoptosis , differentiation , shrinkage and the like of a fat cell , for example . in the method for activating a ppar according to the present invention , the β - cryptoxantine to be used is similar to that used for the above - noted ppar activator according to the present invention , and examples thereof include those derived from citrus fruits , persimmons , papayas , loquats , red bell peppers and the like . in particular , citrus fruits are preferable . the β - cryptoxantine derived from mandarin - type citrus fruits is more preferable , and that derived from satsuma oranges is particularly preferable . further , as the material , it is possible to use the entire fruit , for example , and it is particularly preferable to use the pulp . now , a method for preventing , treating or improving a disease according to the present invention is a method for preventing , treating or improving at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity in a mammal , and the method includes administering β - cryptoxantine . the above - noted mammal can be , for example , a human , a mouse , a rat , a rabbit , a dog , a cat , a cow , a horse , a swine , a monkey or the like . next , a kit according to the present invention is a kit for preventing or treating at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , and the kit includes a ) β - cryptoxantine , b ) a second drug composition containing a second compound useful for preventing or treating at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , and c ) a container for containing the β - cryptoxantine and the second drug composition . now , a use according to the present invention is a use of β - cryptoxantine for manufacturing a ppar activator . further , a use according to the present invention is a use including administering β - cryptoxantine for preventing , treating or improving at least one disease selected from the group consisting of insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity in a mammal . the mammal is as listed above . in the use according to the present invention , the β - cryptoxantine to be used is similar to that used for the above - noted ppar activator according to the present invention , and examples thereof include those derived from citrus fruits , persimmons , papayas , loquats , red bell peppers and the like . in particular , citrus fruits are preferable . the β - cryptoxantine derived from mandarin - type citrus fruits is more preferable , and that derived from satsuma oranges is particularly preferable . further , as the material , it is possible to use the entire fruit , for example , and it is particularly preferable to use the pulp . in the use according to the present invention , the β - cryptoxantine induces at least one of the functions of inhibiting the secretion of tnf - α and free fatty acid in fat cells , promoting the secretion of adiponectin in fat cells and promoting β oxidation of fat in liver cells , for example . moreover , in the use according to the present invention , the β - cryptoxantine induces at least one of apoptosis , differentiation , shrinkage and the like of a fat cell , for example . now , it is preferable that the β - cryptoxantine in the present invention is manufactured from a material such as citrus fruits as described earlier . the following is a description of an example of this manufacturing method ( described in jp 3359298 b ). the β - cryptoxantine can be manufactured from citrus fruits by the method including the processes ( 1 ) to ( 4 ) below : ( 1 ) extracting a juice from a citrus fruit and filtering or sieving the juice ; ( 2 ) centrifuging the juice at low speed to obtain supernatant and centrifuging the supernatant at high speed to obtain a precipitate ; ( 3 ) adding an enzyme for solubilizing the precipitate , followed by freezing ; and ( 4 ) after thawing and solid - liquid separating the precipitate , removing water from the precipitate to obtain solids . examples of the citrus fruit used in the above - described manufacturing method include a satsuma orange , an iyo orange , a watson pomelo , a hassaku orange , a ponkan orange , a navel orange , a lemon , a valencia orange and a grapefruit . among them , mandarin - type citrus fruits are preferable because of their large content of β - cryptoxantine , and a satsuma orange is more preferable . further , although the entire citrus fruit can be used as the material , it is particularly preferable to use a pulp . the above - noted citrus fruit usually goes through screening , washing and then extraction . an extractor is , for example , an in - line extractor , a chopper pulper extractor or a brown extractor . since small pieces of inner skins and bulky pulps usually are mixed in the resultant juice , the juice is filtered or sieved in order to remove them . for this filtering or sieving , a paddle - shaped finisher or a screw - shaped finisher , for example , can be used . the size of its screen mesh is 0 . 3 to 0 . 5 mm , for example . next , the juice is processed by centrifugation . this centrifugation processing consists of low - speed centrifugation and high - speed centrifugation under the following conditions . the low - speed centrifugation refers to centrifugation at a level capable of separating large grains of pulps . the high - speed centrifugation refers to centrifugation at a level capable of centrifuging small grains of pulps . the centrifugal intensity of the low - speed centrifugation is not greater than 3000 × g · min ., for example , and that of the high - speed centrifugation is equal to or greater than 1500 × g · min ., for example , so that the centrifugal intensity of the low - speed centrifugation operation is set to be lower than that of the high - speed centrifugation . now , the juice is centrifuged at low speed , and the resultant supernatant is centrifuged at high speed further , thus collecting a precipitate . subsequently , a solubilizing enzyme is added to the precipitate obtained by the high - speed centrifugation . as the above - noted solubilizing enzyme , it is possible to use pectinase , cellulase , hemicellulase , protease , lipase , maceration enzymes , protopectinase and the like , for example . these enzymes may be used alone or in combination of two or more . the ratio of the above - noted solubilizing enzyme to be added ranges from 0 . 5 to 10 g with respect to 1 kg of the precipitate . thereafter , the precipitate to which the solubilizing enzyme has been added is filled in a container and frozen without warming . then , the frozen precipitate is thawed out . the thawing may be carried out by allowing the precipitate to stand at room temperature . the thawed precipitate is solid - liquid separated , and water is removed by centrifugation so as to obtain solids ( precipitate portion ). these solids contain a high concentration of β - cryptoxantine . incidentally , by repeating the operations of adding purified water to the solids and conducting centrifugation , it is possible to raise the concentration of β - cryptoxantine in the solids further . first , cv - 1 cells ( cultured cells derived from kidneys of male african green monkeys ) were implanted on 24 - well culture plates so as to be 0 . 2 μg / well and cultured at 37 ° c . in 5 % co 2 for 24 hours . as a medium , dmem ( dulbecco &# 39 ; s modified eagle medium ; manufactured by gibco ) containing 10 % fbs ( fetal bovine serum ) and a 10 mg / ml penicillin streptomycin solution was used . next , using lipofectamine system ( manufactured by invitrogen corporation ), pm - hpparγ and p4 × uasg - tk - luc were transfected into the cultured cv - 1 cells . the above - noted pm - hpparγ was a vector for expressing fused protein containing residues 1 - 147 of gal4 binding domain and residues 204 - 505 of human pparγ ligand - binding domain , whereas the above - noted p4 × uasg - tk - luc was a reporter plasmid containing four copies of an upstream activating sequence ( uas ) for gal4 binding domain and a thymidine kinase gene promoter in front of a luciferase gene . after the transfection , the cells were cultured for about 24 hours , and then , the media for the cells were changed to media containing β - cryptoxantine at respective concentrations ( 0 . 1 , 1 . 0 , 10 and 70 μm ) or media for non - treatment control , followed by an additional 24 hour incubation . the above - noted media containing β - cryptoxantine were prepared by adding β - cryptoxantine dissolved in dimethyl sulfoxide ( dmso ) to the media , whereas the media for non - treatment control were prepared by adding only dmso to the media . after the incubation , the cells were lysed for luciferase activation assay using a dual - luciferase reporter gene assay system ( manufactured by promega corporation ) ( measurement group ). similarly to the measurement group , as a control group , the luciferase activation assay was performed using pm ( a vector containing residues 1 - 147 of gal4 binding domain and not containing residues 204 - 505 of pparγ ligand - binding domain in pm - hpparγ ) instead of pm - hpparγ . for each sample , the ratio between average light - emission intensities of the measurement group and the control group ( n = 4 ) ( measurement group / control group ) was calculated , and a luciferase activity relative to the non - treatment control was determined as the pparγ ligand - binding activity of the sample . table 1 below and the graph of fig1 show the results . as becomes clear from table 1 and fig1 mentioned above , the β - cryptoxantine improved the activity of pparγ such that the pparγ activity increased in keeping with the concentration of β - cryptoxantine . as described above , the ppar activator according to the present invention has an excellent ppar activity , is free from a problem of side effects , can be taken over a long term and can be used preferably for foods or the like . thus , the ppar activator according to the present invention can be used as a drug , a supplement , a functional food and a food additive for preventing or improving diseases such as insulin resistance , hyperinsulinism , type 2 diabetes , hypertension , hyperlipemia , arteriosclerosis and obesity , etc , for example . it should be noted that this is effective for not only humans but also other animals .
it is intended to provide a peroxisome proliferator - activated receptor activator , which is free from the problem of side effects , can be taken over a long term and has no characteristics taste . β - cryptoxantine is employed as a ppar activator . β - cryptoxantine , which is contained in a large amount in the pulp of citrus fruits such as satsuma oranges , for example , has been consumed for many years . thus , it is free from any problem in safety and has a low calorie content . therefore , it can be taken over a long term . because of being tasteless and odorless , moreover , β - cryptoxantine would not damage the unique taste when added to a food . therefore , it can be added to foods and taken .